DAX19.849 -0,2%ESt504.858 +0,1%Top 10 Crypto14,68 -3,3%Dow43.297 +0,9%Nas20.031 +1,4%Bitcoin93.061 -2,6%Euro1,0397 -0,1%Öl73,65 +1,0%Gold2.628 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Lilium A3CYXP NVIDIA 918422 Tesla A1CX3T Novo Nordisk A3EU6F Palantir A2QA4J MicroStrategy 722713 Amazon 906866 Apple 865985 Bayer BAY001 Volkswagen (VW) vz. 766403 Rheinmetall 703000 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Ruhiger Wochenauftakt: DAX letztlich im Minus -- VW: Einigung im Tarifkonflikt -- BMW: Unregelmäßigkeiten bei Autoexporten -- Mercedes-Benz, BVB, AstraZeneca im Fokus
Top News
BlackRocks Ausblick für 2025: KI-Rally treibt Märkte an - Schuldenprobleme dürften belasten BlackRocks Ausblick für 2025: KI-Rally treibt Märkte an - Schuldenprobleme dürften belasten
Asiens Börsen legen letztlich zu Asiens Börsen legen letztlich zu
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

WuXi Biologics (Cayman) Aktie

NeuKaufenVerkaufen
4,16 EUR +0,02 EUR +0,48 %
STU
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone
KGV32,32Div. Rendite0,00%

WKNA2PQ3Q

ISINUS98260N1081

SymbolWXXWY

WuXi Biologics (Cayman) Aktien News

DatumMeistgelesen
PR NewswireWuXi Biologics to Increase Manufacturing Capacity in Germany
PR NewswireWuXi Biologics to Increase Manufacturing Capacity in Germany
PR NewswireWuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
PR NewswireWuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
PR NewswireWuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
PR NewswireWuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
PR NewswireWuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
PR NewswireWuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Ther...
PR NewswireWuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
PR NewswireWuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
PR NewswireWuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
PR NewswireWuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
PR NewswireWuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
PR NewswireWuXi Biologics Reports Remarkable 2022 Annual Results
PR NewswireWuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conjugate
PR NewswireWuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
PR NewswireWuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
PR NewswireWuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
PR NewswireWuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
PR NewswireWuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
PR NewswireWuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List
PR NewswireWuXi Biologics Launches an Integrated Biologics CRDMO Center in Fengxian, Shanghai
PR NewswireWuXi Biologics Provides Corporate Updates
PR NewswireWuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China
PR NewswireWuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
PR NewswireWuXi XDC Receives Best CMO Provider Runner Up Prize at 2022 World ADC Awards
PR NewswireWuXi Biologics Receives "Best CDMO Award of the Year"
PR NewswireWuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
PR NewswireWuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
PR NewswireWuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
PR NewswireWuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
PR NewswireWuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
PR NewswireWuXi Biologics Co., Ltd. Removed from Unverified List
PR NewswireWuXi Biologics Co., Ltd. Removed from Unverified List
PR NewswireWuXi Biologics Co., Ltd. Removed from Unverified List
PR NewswireWuXi Biologics Co., Ltd. Removed from Unverified List
PR NewswireWuXi Biologics Co., Ltd. Removed from Unverified List
PR NewswireWuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
PR NewswireWuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
PR NewswireWuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts

WuXi Biologics (Cayman) News

WuXi Biologics (Cayman) News: auf dieser Seite finden Sie alle WuXi Biologics (Cayman) News und Nachrichten zur WuXi Biologics (Cayman) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch WuXi Biologics (Cayman) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um WuXi Biologics (Cayman) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.